NCT04925141 - A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 10, 2016

Primary Completion Date

October 22, 2018

Study Completion Date

December 6, 2019

Conditions

Chronic Myelogenous Leukemia - Chronic Phase

Interventions

DRUG

Dasatinib Tablets

Tyrosine Kinase Inhibitor (TKI)

Trial Locations (4)

Affiliated Zhongshan Hospital of Fudan University, Shanghai

The First Affiliated Hospital, Medical College , Zhejiang University, Hangzhou

Affiliated Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

The Second People's Hospital of Shenzhen, Shenzhen